Marina Keul

Dortmund, NW 44227, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.

Design, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.

Journal: Journal of medicinal chemistry

Published: January 22, 2025

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 29, 2022

Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening.

Analyzing Kinase Similarity in Small Molecule and Protein Structural Space to Explore the Limits of Multi-Target Screening.

Journal: Molecules (Basel, Switzerland)

Published: November 30, 2020

Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.

Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.

Journal: Journal of medicinal chemistry

Published: September 15, 2020

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.

Journal: Chemical science

Published: July 12, 2019

RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics.

RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics.

Journal: ChemMedChem

Published: July 17, 2018

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Journal: Nature communications

Published: March 14, 2018

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

Journal: Journal of medicinal chemistry

Published: October 10, 2017

Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.

Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.

Journal: Angewandte Chemie (International ed. in English)

Published: October 09, 2017

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

Journal: Journal of medicinal chemistry

Published: August 31, 2017

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.

Journal: Journal of medicinal chemistry

Published: June 13, 2017

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.

Journal: Journal of medicinal chemistry

Published: February 23, 2017

Showing 1-12 of 16

Last Updated: 09/26/2026